Assembly Biosciences Return on Tangible Equity 2010-2024 | ASMB
Current and historical return on tangible equity values for Assembly Biosciences (ASMB) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Assembly Biosciences Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-06-30 |
$-0.05B |
$0.04B |
-119.21% |
| 2024-03-31 |
$-0.05B |
$0.03B |
-119.30% |
| 2023-12-31 |
$-0.06B |
$0.04B |
-117.31% |
| 2023-09-30 |
$-0.07B |
$0.04B |
-115.20% |
| 2023-06-30 |
$-0.08B |
$0.06B |
-104.52% |
| 2023-03-31 |
$-0.09B |
$0.07B |
-92.88% |
| 2022-12-31 |
$-0.09B |
$0.08B |
-80.70% |
| 2022-09-30 |
$-0.13B |
$0.10B |
-95.94% |
| 2022-06-30 |
$-0.13B |
$0.12B |
-80.90% |
| 2022-03-31 |
$-0.13B |
$0.15B |
-73.15% |
| 2021-12-31 |
$-0.13B |
$0.17B |
-69.52% |
| 2021-09-30 |
$-0.11B |
$0.18B |
-56.04% |
| 2021-06-30 |
$-0.09B |
$0.19B |
-45.15% |
| 2021-03-31 |
$-0.06B |
$0.21B |
-28.87% |
| 2020-12-31 |
$-0.06B |
$0.20B |
-28.74% |
| 2020-09-30 |
$-0.05B |
$0.23B |
-22.32% |
| 2020-06-30 |
$-0.07B |
$0.23B |
-36.83% |
| 2020-03-31 |
$-0.10B |
$0.21B |
-56.81% |
| 2019-12-31 |
$-0.10B |
$0.23B |
-62.32% |
| 2019-09-30 |
$-0.10B |
$0.12B |
-68.55% |
| 2019-06-30 |
$-0.09B |
$0.13B |
-58.84% |
| 2019-03-31 |
$-0.10B |
$0.15B |
-73.78% |
| 2018-12-31 |
$-0.09B |
$0.17B |
-78.28% |
| 2018-09-30 |
$-0.07B |
$0.19B |
-74.11% |
| 2018-06-30 |
$-0.06B |
$0.05B |
-126.09% |
| 2018-03-31 |
$-0.05B |
$0.06B |
-118.42% |
| 2017-12-31 |
$-0.04B |
$0.07B |
-147.01% |
| 2017-09-30 |
$-0.05B |
$0.01B |
-247.62% |
| 2017-06-30 |
$-0.05B |
$0.02B |
-163.78% |
| 2017-03-31 |
$-0.05B |
$0.03B |
-112.28% |
| 2016-12-31 |
$-0.05B |
$0.04B |
-84.51% |
| 2016-09-30 |
$-0.04B |
$0.05B |
-65.08% |
| 2016-06-30 |
$-0.04B |
$0.06B |
-50.00% |
| 2016-03-31 |
$-0.03B |
$0.07B |
-41.51% |
| 2015-12-31 |
$-0.03B |
$0.08B |
-34.83% |
| 2015-09-30 |
$-0.03B |
$0.08B |
-39.56% |
| 2015-06-30 |
$-0.03B |
$0.09B |
-63.92% |
| 2015-03-31 |
$-0.03B |
$0.08B |
-83.20% |
| 2014-12-31 |
$-0.02B |
$0.02B |
-143.75% |
| 2014-09-30 |
$-0.02B |
$0.01B |
-129.58% |
| 2014-06-30 |
$-0.02B |
$0.02B |
-70.83% |
| 2014-03-31 |
$-0.02B |
$0.02B |
-74.77% |
| 2013-12-31 |
$-0.02B |
$0.02B |
-66.67% |
| 2013-09-30 |
$-0.02B |
$0.03B |
-63.16% |
| 2013-06-30 |
$-0.02B |
$0.03B |
-68.57% |
| 2013-03-31 |
$-0.02B |
$0.04B |
-80.00% |
| 2012-12-31 |
$-0.02B |
$0.02B |
-103.23% |
| 2012-09-30 |
$-0.04B |
$0.02B |
-141.82% |
| 2012-06-30 |
$-0.04B |
$0.03B |
-113.48% |
| 2012-03-31 |
$-0.04B |
$0.03B |
-129.03% |
| 2011-12-31 |
$-0.04B |
$0.04B |
-128.44% |
| 2011-09-30 |
$-0.03B |
$0.05B |
-120.93% |
| 2011-06-30 |
$-0.02B |
$0.01B |
-258.82% |
| 2011-03-31 |
$-0.02B |
$0.01B |
-272.00% |
| 2010-12-31 |
$-0.02B |
$0.01B |
-533.33% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.107B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
